South Africa Receives First Shipment of Lenacapavir HIV Prevention Medicine
- South Africa has received its first shipment of Lenacapavir, a long-acting HIV prevention medicine.
- The medicine arrived in the country on Thursday, April 3, 2026.
- It is administered as an injectable dose every six months, a delivery method that is expected to improve adherence to prevention protocols compared to daily medication.
South Africa has received its first shipment of Lenacapavir, a long-acting HIV prevention medicine. The Department of Health announced on April 7, 2026, that the initial delivery consists of 37,920 doses.
The medicine arrived in the country on Thursday, April 3, 2026. This delivery is intended to strengthen the national effort to reduce new HIV infections and contribute to the goal of ending AIDS as a public health threat by 2030, aligning with the Global AIDS Strategy for 2026–2030.
Medical Application and Administration
Lenacapavir is a preventive medicine rather than a vaccine. It is administered as an injectable dose every six months, a delivery method that is expected to improve adherence to prevention protocols compared to daily medication.
The Department of Health describes the drug as part of an integrated, differentiated, and people-centered HIV prevention strategy. This approach is designed to offer new options for individuals who face significant barriers to existing prevention methods.
Target Populations and Public Health Impact
The introduction of the six-monthly injectable is expected to expand prevention choices specifically for vulnerable priority groups. These include:
- Adolescent girls and young women
- Sex workers
- Men who have sex with men
The drug is considered one of the most significant advances in HIV prevention in recent years due to its potential to increase protection for those most at risk. This development comes at a time when the total number of people living with HIV in South Africa was estimated at approximately eight million, or roughly 12.7% of the total population, in 2024.
Implementation and Official Launch
Health Minister Dr. Aaron Motsoaledi has expressed enthusiasm regarding the arrival of the medicine, describing it as a major breakthrough in the country’s HIV response.
Department of Health
This six-monthly injectable has arrived in the country last week Thursday and is expected to expand HIV prevention choices, improve adherence especially amongst the most vulnerable priority groups
The Department of Health stated that an official launch of the medicine will take place in the coming weeks. This event is expected to be led by President Cyril Ramaphosa.
During the official launch, the government will outline a phased implementation plan to determine how the doses will be distributed and administered across the health system.
Global Context
The rollout in South Africa occurs alongside broader international efforts. Reports indicate that Zimbabwe and Kenya are also rolling out Lenacapavir. The World Health Organization has issued guidelines recommending the twice-yearly injectable for HIV prevention.